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Diastolic dysfunction is an important predictor of poor outcome after myocardial infarction.
Metformin treatment improved diastolic function in animal models and patients with diabe-
tes. Whether metformin improves diastolic function in patients presenting with ST-segment
elevation myocardial infarction (STEMI) is unknown.
Methods
The GIPS-III trial randomized STEMI patients, without known diabetes, to metformin or pla-
cebo initiated directly after PCI. The previously reported primary endpoint was left ventricu-
lar ejection fraction at 4 months, which was unaffected by metformin treatment. This is a
predefined substudy to determine an effect of metformin on diastolic function. For this sub-
study trans-thoracic echocardiography was performed during hospitalization and after 4
months. Diastolic dysfunction was defined as having the combination of a functional alter-
ation (i.e. decreased tissue velocity: mean of septal e’ and lateral e’) and a structural alter-
ation (i.e. increased left atrial volume index (LAVI)). In addition, left ventricular mass index
and transmitral flow velocity (E) to mean e’ ratio (E/e’) were measured to determine an effect
of metformin on individual echocardiographic markers of diastolic function.
Results
In 237 (63%) patients included in the GIPS-III trial diastolic function was measured during
hospitalization as well as at 4 months. Diastolic dysfunction was present in 11 (9%) of
patients on metformin and 11 (9%) patients on placebo treatment (P = 0.98) during hospitali-
zation. After 4 months 22 (19%) of patients with metformin and 18 (15%) patients with pla-
cebo (P = 0.47) had diastolic dysfunction. In addition, metformin did not improve any of the
individual echocardiographic markers of diastolic function.
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Conclusions
In contrast to experimental and observational data, our randomized placebo controlled trial
did not suggest a beneficial effect of short-term metformin treatment on diastolic function in
STEMI patients.
Introduction
Diastolic dysfunction is common after acute myocardial infarction and is estimated to affect-
ing up to 40% of patients [1–3]. It is also an important and independent predictor of adverse
outcome, irrespective of and even in the absence of systolic dysfunction [3–11]. The presence
of (pre)diabetes, the extent of myocardial injury, delayed and unsuccessful reperfusion, a his-
tory of hypertension and female sex have been associated with diastolic dysfunction after myo-
cardial infarction [11–17]. Acute myocardial injury has been associated with direct regional
diastolic dysfunction and the subsequent infarct healing and remodeling can affect global dia-
stolic function [11,18]. There is no therapy available to treat or prevent the occurrence of dia-
stolic dysfunction after myocardial infarction [19–21].
Metformin is the most widely used oral antihyperglycemic agent for the treatment of type 2
diabetes [22]. In diabetics, metformin has been associated with improved outcome indepen-
dently of glycemic control, and there are indications it may have direct cardioprotective effects
[22–27]. The use of metformin has been associated with improved diastolic function in
patients with diabetes undergoing coronary angiography [28]. In dogs with pacing-induced
heart failure, metformin significantly reduced capillary wedge pressure and left ventricular
end-diastolic pressure compared to control [29]. Metformin also lowered left ventricular end-
diastolic pressure in a non-diabetic rat model [30]. These studies led to the hypothesis that
metformin treatment might reduce the risk of diastolic dysfunction development in patients
presenting with myocardial infarction.
In the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST-Ele-
vation Myocardial Infarction (GIPS-III) study we investigated the effect of metformin treat-
ment in non-diabetic patients. We previously reported the primary endpoint, left ventricular
ejection fraction at 4 months, which was unaffected by metformin treatment [31]. In the pres-
ent pre-specified sub-study of GIPS-III, we analyzed the effect of metformin treatment on dia-
stolic function in non-diabetic patients undergoing successful primary percutaneous coronary
intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Methods
The current echocardiographic sub-study is a predefined ancillary study of the GIPS-III trial.
The GIPS-III trial has been registered as a clinical trial with identifier: NCT01217307. The
GIPS-III trial was a single center, randomized, double blind, placebo-controlled study. The
study design, baseline characteristics and primary outcomes have previously been reported
[31,32]. In short, patients presenting with STEMI to the University Medical Center Groningen
between January 1, 2011, and May 26, 2013 who underwent successful PCI with implantation
of at least 1 stent with a diameter of at least 3 mm were eligible for inclusion in the trial.
Patients also needed to be able to undergo magnetic resonance imaging to assess the primary
endpoint (LVEF) and had to be 18 years of age or older. Major exclusion criteria included
known diabetes, previous myocardial infarction, and severe renal dysfunction. Patients were
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randomized to either metformin 500mg twice daily or a visually matching placebo twice daily,
starting immediately after PCI. Verbal informed consent was obtained from the patients dur-
ing the PCI and written consent followed after admission to the Coronary Care Unit (CCU).
After four months of treatment patients underwent cardiac magnetic resonance imaging
(MRI) to assess the primary endpoint, LVEF. The study protocol was approved by the local
ethics committee (Groningen, the Netherlands), and was in accordance with the Declaration
of Helsinki [33] and Dutch laws.
Echocardiography
A trans-thoracic echocardiogram in left decubital position was performed by experienced
operators using a Vivid 7 echo system (General Electric, Horton, Norway) during hospitali-
zation for the index event and at four months follow-up. All echocardiographic data were
digitally stored in DICOM format and off-line analysis was performed by experienced
sonographers on an Echopac BT 10 (General Electric, Horton, Norway) at an independent
core lab (Groningen Imaging Core Laboratory, Groningen, the Netherlands). Observers
performing the analyses were blinded to treatment allocation and clinical information.
Echocardiographic evaluation was performed as recommended by the guidelines in effect
[34–39]. When appropriate measures were indexed for body surface area (BSA) according
to the formula of Du Bois and Du Bois [40]. The following structural measurements were
assessed: Left ventricular (LV) interventricular septal and posterior wall thickness (IVS and
LVPW), left ventricular end-diastolic (LVEDD) and end-systolic diameter (LVESD). In
addition, Simpson’s biplane volumetric measurements including LV end-diastolic volume
(LVEDV) and end-systolic volume (LVESV). LVEF was calculated as LVEF = (LVEDV-L-
VESV)/LVEDV x 100%. Left atrial volume (LAV) was measured with the area length
method. The LV mass was estimated from linear dimensions as suggested by Devereux and
colleagues [37]. LV diastolic parameters included Doppler measurement of the passive early
filling (E), active atrial filling (A), isovolumetric relaxation time (IVRT) and E wave deceler-
ation time (DT). Using spectral tissue Doppler, early diastolic tissue velocities (e’) from
both the septal and lateral wall were assessed [35,36,41–43]. Mean e’ was calculated as (e’
septal + e’ lateral)/2. Reported values represent the mean of three heart beats in end-
expiration.
Individual parameters of diastolic function were interpreted as recommended by the latest
guidelines from the European Society of Cardiology and the American Society of Echocardiog-
raphy: Mean e’ was deemed abnormal if9cm/s; E/e’ was calculated as E/mean e’ and was
deemed abnormal if13; indexed left atrial volume (LAVI) was deemed abnormal if34 ml/
m2; left ventricular mass index (LVMI) was deemed abnormal if95 gram/m2 in women and
115 gram/m2 in men, mean e’ was deemed abnormal if9cm/s, and E/e’ was deemed abnor-
mal if13 [39,44].
The definition of diastolic dysfunction was based on the recommendations made by
Nagueh and colleagues as well as recommendations made by the European Society of Cardiol-
ogy [34,39]. The presence of diastolic dysfunction was defined as having a LAVI larger than
34ml/m2 in combination with a mean e’< 9cm/s.
Statistical analysis
The primary analysis was the presence of diastolic dysfunction in patients in the metformin
group compared to the placebo group. The individual parameters of diastolic function in both
groups were analyzed as a secondary analysis.
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Continuous variables are presented as mean ± standard deviation (SD) for values that
approximate a normally distribution and as median with their interquartile range (IQR) if val-
ues do not approximate a normal distribution. For continuous variables differences between
groups were tested using 2-tailed t test for normally distributed data and Wilcoxon rank-sum
for non-normally distributed data. For binary variables differences were assessed using the
Pearson’s chi-squared test and an ordered logistic regression for ordinal variables. All reported
P values are 2-sided, and a P-value of<0.05 was considered to indicate significant difference
between groups. All analyses were performed using Stata version 14.1 (StataCorp).
Results
Three hundred and seventy-nine patients participated in the GIPS-III trial and at 4 months
after infarction, all patients were alive and none were lost to follow-up. Of these patients 329
(87%) underwent echocardiography both during hospitalization and at 4 months; 43 (11%)
patients only underwent echocardiography during hospitalization and 5 (1.3%) patients only
at 4 months. Of the 706 echocardiographic procedures that were performed, the presence of
diastolic dysfunction could be reliably classified in 599 (85%) procedures. The presence of dia-
stolic dysfunction could be classified only during hospitalization in 60 (16%) patients, and
only at 4 months in 65 (17%) patients. The presence of diastolic dysfunction could be classified
at both time points in 237 (64%) patients (Fig 1).
The baseline characteristics for these 237 patients in whom the presence of diastolic dys-
function could be classified at both time points are presented in Table 1. The two treatment
groups were well balanced for baseline characteristics. Also, we did not observe a substantial
baseline differences between subjects with available echocardiographic measurements of dia-
stolic dysfunction compared to those without (S1 Table). Diastolic dysfunction was present in
22 (9%) of the 237 patients for whom the presence of diastolic dysfunction could be classified
at both time points. During hospitalization 11 (9%) patients in the metformin group had dia-
stolic dysfunction compared with 11 (9%) patients in the placebo group (P = 0.98) (Fig 2).
During hospitalization, measurements of cardiac structure and function for patients treated
with metformin (n = 118) or placebo (n = 119) were similar (Table 2). During hospitalization
83 (73%) patients in the metformin group had at least one abnormal diastolic parameter com-
pared with 73 (66%) patients in the placebo group (P = 0.25). Treatment with metformin ver-
sus administering a placebo did not have effect on the distribution of the amount of abnormal
parameters of diastolic function during hospitalization (P = 0.38) (Fig 3).
At 4 months after myocardial infarction, diastolic dysfunction was present in 40 (17%) of
the 237 patients for whom the presence of diastolic dysfunction could be classified at both time
points; 118 patients randomized to metformin and 119 to placebo. In the metformin group 22
(19%) patients had diastolic dysfunction compared to 18 (15%) patients in the placebo group
(P = 0.47) (Fig 2). At 4 months, diastolic function parameters were similar between groups.
Table 2 displays the changes of all individual echocardiographic parameters between baseline
and 4 months. Except LVEF, we found no other statistically significant changes in any of the
echocardiographic parameters. At 4 months 82 (71%) patients in the metformin group had at
least one abnormal diastolic parameter compared with 68 (60%) patients in the placebo group
(P = 0.08). Treatment with metformin versus administering a placebo did not have effect on
the distribution of the amount of abnormal parameters of diastolic function at 4 months
(P = 0.30) (Fig 3).
Change in the classification of diastolic dysfunction was present in 34 (14%) out of 237
patients in whom diastolic dysfunction could be classified at both time points, with diastolic
dysfunction developing in 26 (11%) patients and diastolic dysfunction reverting to normal in 8
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(8%) patients. In the metformin group 14 (12%) out of 118 patients developed diastolic dys-
function between hospitalization and follow-up and 3 (3%) patient reverted from dysfunction
back to normal function compared with 12 (10%) out of 119 patients in the placebo group that
developed dysfunction and 5 (4%) patients who reverted from dysfunction back to normal
(P = 0.54). Also none of the individual measurements related to diastolic function were differ-
ent between the 175 patients that received 4 months of placebo treatment versus the 173
patients that were treated with metformin.
Discussion
In this predefined sub study of a prospective, randomized, placebo controlled trial, we found
that metformin did not improve diastolic function as compared to placebo in patients present-
ing with STEMI. These findings are in contrast with earlier observational and experimental
studies suggesting beneficial effects of metformin treatment on diastolic function. In a rat
model of ischemia-reperfusion injury, metformin treatment resulted in lower left ventricular
end-diastolic pressure, independent from glycemic control [30]. Also in dogs with pacing
Fig 1. Flowchart of echocardiographic assessment during hospitalization and at 4 months according to
randomization. STEMI denotes ST-segment elevation myocardial infarction.
doi:10.1371/journal.pone.0168340.g001
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induced heart failure, metformin treatment improved diastolic function as indicated by a
reduced left ventricular end-diastolic pressure [29]. In patients with diabetes, improvements of
Table 1. Baseline characteristics of the population that underwent echocardiography in hospital and at 4 months by treatment allocation.
No.(%)
Characteristic Total (n = 237) Placebo (n = 119) Metformin (n = 118) P-value
Age, years 58.1 ± 11.0 58.2 ± 10.7 57.9 ± 11.4 0.82
Women 53 (22.4%) 30 (25.2%) 23 (19.5%) 0.29
Body weight, kg 84.4 ± 14.0 84.3 ± 13.7 84.5 ± 14.3 0.88
Body-mass Index, kg/m2 26.8 ± 3.5 26.9 ± 3.3 26.7 ± 3.7 0.61
Race/ethnicity
White 230 (97.0%) 116 (97.5%) 114 (96.6%) 0.69
Asian 6 (2.5%) 3 (2.5%) 3 (2.5%) 0.99
Black 1 (0.4%) 0 (0.0%) 1 (0.8%) 0.50
Cardiovascular related history
Hypertension 66 (27.8%) 31 (26.1%) 35 (29.7%) 0.54
Dyslipidemia 154 (65.0%) 83 (69.7%) 71 (60.2%) 0.12
Current smoking 124 (52.3%) 59 (49.6%) 65 (55.1%) 0.40
Stroke 1 (0.4%) 1 (0.8%) 0 (0.0%) 1.00
Previous PCI 4 (1.7%) 3 (2.5%) 1 (0.8%) 0.32
Blood pressure, mmHg
Systolic 134.7 ± 23.2 134.7 ± 23.7 134.6 ± 22.8 0.98
Diastolic 85.1 ± 14.4 85.1 ± 14.8 85.1 ± 14.0 0.98
Heart rate, beats/min 75.3 ± 16.0 76.4 ± 17.4 74.2 ± 14.5 0.29
Infarct-related factors
Ischemia time, min 152 (107, 245) 144 (105, 232) 169 (109, 264) 0.23
Single vessel disease 166 (70.0%) 87 (73.1%) 79 (66.9%) 0.30
Anterior infarction 95 (40.1%) 46 (38.7%) 49 (41.5%) 0.65
Intervention-related assesments
TIMI flow grade pre PCI 1 154 (65.0%) 84 (70.6%) 70 (59.3%) 0.07
TIMI flow grade post PCI < 3 14 (5.9%) 6 (5.0%) 8 (6.8%) 0.57
Myocardial blush grade 1 20 (8.5%) 8 (6.7%) 12 (10.3%) 0.32
Laboratory values at admission
Glucose, mmol/l 8.2 (7, 9.6) 8.4 (7, 10.1) 8.1 (6.8, 9.4) 0.31
HbA1c, % 5.8 (5.6, 6) 5.8 (5.6, 6) 5.75 (5.6, 6) 0.73
Hemoglobin, mmol/l 9 (8.4, 9.4) 8.9 (8.3, 9.5) 9 (8.5, 9.3) 0.54
Creatinine, μmol/l 72 (62, 81) 73 (64, 80) 71 (60, 82) 0.82
eGFR, ml/min/1.73m2 96 (87, 103) 95 (88, 101) 97 (86, 105) 0.22
NT-proBNP, ng/L 78 (40, 177) 68 (37, 177) 79.5 (42, 179) 0.50
CK, U/L 129 (85, 192) 123 (82, 179) 132 (89, 218) 0.20
Myocardial band of CK, U/L 16 (13, 23) 15 (12, 22) 16 (13, 27) 0.16
Troponine T, ng/L 43 (21, 115) 39.5 (22, 87) 49 (20, 136) 0.45
Total cholesterol, mmol/l 5.4 (4.8, 6) 5.45 (4.9, 6) 5.35 (4.7, 6.1) 0.71
LDL cholesterol, mmol/l 3.8 (3.25, 4.4) 3.8 (3.3, 4.4) 3.7 (3.2, 4.6) 0.96
HDL cholesterol, mmol/l 1.1 (0.9, 1.4) 1.1 (0.9, 1.4) 1.1 (0.9, 1.3) 0.67
SD, standard deviation; PCI, percutaneous coronary intervention; IQR, interquartile range; TIMI, Thrombolysis in Myocardial Infarction; HbA1c, glycated
hemoglobin; NT-proBNP, N-terminal pro brain natriuretic peptide; eGFR, estimated glomerular filtration rate; CK, creatine kinase; LDL, low density
lipoprotein; HDL high density lipoprotein.
doi:10.1371/journal.pone.0168340.t001
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glycemic control, including the use of metformin, was associated with improvements of dia-
stolic function as measured by septal e’ [45]. Also in the setting of stable coronary artery dis-
ease, metformin use in diabetic patients was associated with improved left ventricular diastolic
function as measured by mean e’ and IVRT [28].
The frequency of diastolic dysfunction during hospitalization and follow-up in our study
was substantial but less than reported by others. Other studies have reported substantially
higher numbers of diastolic dysfunction after myocardial infarction [4,7,9,46–48]. Differences
in the population might explain some of the prevalence of diastolic dysfunction. In our study,
patients with known diabetes were excluded and diabetes is associated with diastolic dysfunc-
tion [38]. Also the prevalence of insulin resistance and the metabolic syndrome, which are
closely related to diastolic dysfunction, was low in the GIPS-III trial. Especially in patient with
the metabolic syndrome, increasing insulin sensitivity by metformin might be associated with
improvements of diastolic function. MET-DIME is an ongoing prospective trial in which met-
formin treatment will be tested in patients without diabetic but with the metabolic syndrome
[49]. The primary endpoint of MET-DIME is the change in mean of early diastolic mitral
annular velocity.
Another important difference which might explain differences in the reported prevalence
of diastolic function after myocardial infarction can be attributed to the definitions used to
designate diastolic dysfunction. No single echocardiographic parameter can be effectively used
to make a diagnosis of LV diastolic dysfunction [19]. However, several previous studies
defined diastolic function as a single echocardiographic parameter.
Fig 2. Barchart of classification of diastolic function during hospitalization and at 4 months according to
randomization.
doi:10.1371/journal.pone.0168340.g002
Effect of Metformin on Diastolic Function
PLOS ONE | DOI:10.1371/journal.pone.0168340 December 15, 2016 7 / 13
In contrast, our definition was based on the presence of both increased LAVI as well as
decreased mitral annular tissue Doppler velocity. This definition combines a finding of struc-
tural abnormality related to diastolic function with a finding of functional abnormality related
to diastolic function as is recommended by Nagueh and colleagues as well as the most recent
guidelines of the European Society of Cardiology [34,39].
The prevalence of abnormality in single echocardiographic parameters for diastolic func-
tion was substantially higher in our cohort. The sub-study from the Cardiac Arrhythmias and
Risk Stratification after Acute Myocardial Infarction (CARISMA) study also graded diastolic
dysfunction based on a combined assessment of E0, DT, E/A ratio, and IVRT. They excluded
LAVI in their definition and reported diastolic dysfunction in 39% of patients, six weeks after
MI. However, a major difference with our study is that the CARISMA study only included
patients with an LVEF <40%[4]. Reduced LVEF is also associated with the presence of dia-
stolic dysfunction [3]. A meta-analysis of over 3000 patients after acute myocardial infarction
with a mean LVEF of 46% observed diastolic dysfunction in approximately 20% of patients. In
the subgroup of patients with LVEF>53% the prevalence of diastolic dysfunction was only 9%
[3]. Considering the mean LVEF of our trial (51%) these numbers are comparable.
Table 2. Echocardiographic measurements during hospitalization and at 4 months.





















2 (1, 3) 2 (1, 3) 0.29 124(119, 128) 123 (116, 128) 0.41 121 (116, 127) 120 (11, 126) 0.13








0.63 5.5 (-3.3, 19.0) 4.6 (-10.6, 22.0) 0.42
LVESV, ml 47.0 (35.4,
62.6)
48.2 (37.0, 62.2) 0.49 41.9 (35.3,
54.1)
45.9 (36.7, 63.9) 0.08 -1.8 (-8.3, 5.4) -0.3 (-6.8, 8.7) 0.36
LVEF, % 52 (46, 57) 52 (45, 59) 1.00 58 (53, 63) 55 (48, 60) <0.01 3.7 (0.3, 10.6) 3.2 (-2.9, 7.6) 0.04










-0.9 (-31.1, 13.7) 0.46

























29.7 (-6.4, 56.2) 0.35










-4.6 (-18.4, 13.8) 0.19
Septal e‘, cm/s 7.7 (6.3, 9.1) 7.9 (6.2, 9.1) 0.94 8.1 (6, 9.5) 7.9 (6.9, 9.4) 0.67 0.1 (-1.0, 1.2) 0.4 (-1.1, 1.7) 0.45
Lateral e‘, cm/s 9.8 (7.7, 12) 9.3 (6.9, 12) 0.28 10 (8.5, 12) 10 (7.8, 11) 0.07 0.3 (-1.2, 2.5) 0.0 (-1.2, 1.6) 0.31
Mean e‘, cm/s 8.9 (7.1, 10) 8.4 (7, 10) 0.50 9.2 (7.7, 11) 8.9 (7.8, 10) 0.32 0.3 (-0.8, 1.3) 0.2 (-0.6, 1.5) 0.88
E/e‘ratio 7.1 (5.9, 9.7) 7.8 (6.7, 9.6) 0.08 7.5 (6.2, 8.7) 7.6 (6.4, 9) 0.51 0.2 (-1.3, 1.9) -0.1 (-1.3, 1.0) 0.31
LAVI, ml/m2 26 (22, 32) 27 (23, 32) 0.47 28 (24, 34) 28 (25, 35) 0.98 1.6 (-2.7, 7.3) 1.2 (-2.7, 6.6) 0.66




0.26 0.6 (-13.5, 9.1) -2.7 (-16.0, 6.9) 0.41
LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LV mass, left ventricular
mass; E, passive early filling of the left ventricle; A, active atrial filling of the left ventricle; DT, E wave deceleration time; E-wave deceleration time; IVRT
isovolumetric relaxation time; Septal e‘, early diastolic tissue velocity from septal wall; Lateral e‘, early diastolic tissue velocity from lateral wall; LAVI, left
atrial volume indexed for body mass; LVMI, left ventricular mass indexed for body mass.
doi:10.1371/journal.pone.0168340.t002
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In the present subgroup, a 3% lower LVEF was observed in the metformin compared with
placebo patients. We previously reported that metformin has no effect on the outcome of
LVEF [31]. It is important to note that the current reported LVEF is based on the echocardio-
graphic measurement of a subgroup of the GIPS3 trial while the previously reported LVEF was
based on MRI and was defined as the primary endpoint. MRI is considered superior to echo-
cardiography and is currently considered the reference standard for determination of the
LVEF [50].
The major strength of this study is that the GIPS-III is a prospective, randomized, placebo
controlled trial in which we a priory defined diastolic function as a secondary endpoint. How-
ever, some limitations exist. We cannot exclude the metformin dosage was too low or the dura-
tion of treatment too short to have measurable effect on diastolic function. Our trial was not
powered for diastolic function parameters and although we studied diastolic function as a con-
tinuous variable, the distribution of diastolic function might be too narrow in our cohort. We
cannot exclude that metformin might be effective in patients with diabetes. Also the patient
population was at low risk for developing diastolic dysfunction leading to a relatively low num-
ber of cases and these post-hoc analyses might be underpowered to detect small differences.
Furthermore, since evaluation of ischemia was not part of the study protocol we cannot
exclude that a concomitant effect of myocardial ischemia and/or percutaneous revasculariza-
tion may have influenced our analyses. Also we cannot exclude that pre-existing diastolic dys-
function was present in some patients and may have influenced our analyses. Roughly one
third of the original cohort was excluded because echocardiography was not performed or
because echocardiography did not allow for diastolic measurements, although we did not find
Fig 3. Barchart of prevalence of abnormal individual parameters of diastolic function during
hospitalization and at 4 months according to randomization.
doi:10.1371/journal.pone.0168340.g003
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evidence, we cannot exclude that a certain patient selection based on presence of echocardio-
graphic measurements has influenced our results.
In conclusion, the prevalence of diastolic dysfunction after first STEMI in non-diabetic
patients was approximately 16%. In contrast to previous experimental and observational data,
our placebo controlled, randomized trial data did not suggest a beneficial effect of 4 months of
metformin treatment on diastolic function parameters when initiated after PCI for STEMI.
Supporting Information
S1 Table. Baseline characteristics of study population by presence of measurements of dia-
stolic dysfunction in hospital.
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